Changes in share capital

Year Transaction Change in number of shares Change in share capital Totalt share capital Total number of shares
2021 New share issue 1 124 4 450 5 922 942 14 807 353
2020 New share issue 1 345 111 538 045 5 918 492 14 796 229
2018 New share issue 50 000 20 000 5 380 447 13 451 118
2016 Reverse split -120,610,066 0 5 360 447 13 401 118
2014 New share issue 12,855,000 514,200 5 360 447 134 011 184
2012 New share issue 4,900,000 196,000 4 846 247 121 156 184
2007 Convertible 7,614,555 304,582 4 345 665 108 641 629
2007 Offset issue 746,193 29,848 4 315 817 107 895 436
2007 Non-cash issue 2,961,085 118,443 4 197 374 104 934 351
2007 New share issue 22,500,000 900,000 3 297 374 82 434 351
2006 New share issue 3,703,704 148,148 3 149 226 78 730 647
2006 Offset issue 764,000 30,560 3 118 666 77 966 647
2006 Non-cash issue 11,579,784 463,191 2 655 475 66 386 863
2006 Offset issue 7,379,756 295,190 2 360 284 59 007 107
2006 New share issue 22,127,665 885,107 1 475 178 36 879 442
2005 Non-cash issue 465,370 18,615 1 456 563 36 414 072
2005 Non-cash issue 500,000 20,000 1 436 563 35 914 072
2005 New share issue 17,957,036 718,281 718 281 17 957 036
2004 Offset issue 612,400 24,496 693 785 17 344 636
2004 New share issue 1,515,000 60,600 633 185 15 829 636
2003 Offset issue 1,311,936 52,477 580 708 14 517 700
2003 Bonus issue 414,525 552 700 13 817 500
2003 New share issue 189,000 1,890 138 175 13 817 500
2003 Offset issue 836,530 8,365 136 285 13 628 500
2003 New share issue 1,263,470 12,635 127 919 12 791 970
2003 Offset issue 305,900 3,059 115 285 11 528 500
2003 New share issue 294,100 2,941 112 226 11 222 600
2003 Offset issue 52,500 525 109 285 10 928 500
2002 New share issue 126,000 1,260 108 760 10 876 000
2002 New share issue 750,000 7,500 107 500 10 750 000
2001 Company formed 10,000,000 100,000 100 000 10 000 000
Woman holding a pill

MedCap as an investment

MedCap acquires and develops profitable, market-leading niche companies in the life science industry in Northern Europe that have the potential to grow internationally. The group conducts operations in two areas: MedTech and Specialty Pharma.